Protagonist Therapeutics (PTGX) Insider Trading & Ownership $40.69 -0.77 (-1.86%) (As of 12/17/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Protagonist Therapeutics (NASDAQ:PTGX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.40%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$15.19 M Get PTGX Insider Trade Alerts Want to know when executives and insiders are buying or selling Protagonist Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PTGX Insider Buying and Selling by Quarter Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Protagonist Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/27/2024Arturo Md MolinaInsiderSell26,000$44.70$1,162,200.00 11/25/2024Dinesh V Ph D PatelCEOSell78,520$46.96$3,687,299.20 11/25/2024Suneel GuptaInsiderSell103,437$46.04$4,762,239.48 11/15/2024Arturo Md MolinaInsiderSell1,906$40.98$78,107.88 9/11/2024Asif AliCFOSell14,203$44.49$631,891.47 9/10/2024William D WaddillDirectorSell8,000$45.00$360,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/24/2024William D WaddillDirectorSell8,000$40.00$320,000.00 6/7/2024Dinesh V Ph D PatelCEOSell35,000$35.19$1,231,650.00 6/7/2024William D WaddillDirectorSell8,000$35.00$280,000.00 4/18/2024Asif AliCFOSell1,234$25.11$30,985.74 4/1/2024Dinesh V Ph D PatelCEOSell25,000$28.31$707,750.00 3/1/2024Asif AliCFOSell14,248$32.24$459,355.52 3/1/2024Dinesh V Ph D PatelCEOSell30,000$31.62$948,600.00 3/1/2024William D WaddillDirectorSell12,975$31.34$406,636.50 1/9/2024Suneel GuptaInsiderSell5,000$25.00$125,000.00 (Data available from 1/1/2013 forward) PTGX Insider Trading Activity - Frequently Asked Questions Who is on Protagonist Therapeutics's Insider Roster? The list of insiders at Protagonist Therapeutics includes Arturo Md Molina, Asif Ali, Dinesh V Ph D Patel, Suneel Gupta, and William D Waddill. Learn more on insiders at PTGX. What percentage of Protagonist Therapeutics stock is owned by insiders? 5.40% of Protagonist Therapeutics stock is owned by insiders. Learn more on PTGX's insider holdings. Which Protagonist Therapeutics insiders have been selling company stock? The following insiders have sold PTGX shares in the last 24 months: Arturo Md Molina ($1,240,307.88), Asif Ali ($1,122,232.73), Dinesh V Ph D Patel ($6,575,299.20), Suneel Gupta ($4,887,239.48), and William D Waddill ($1,366,636.50). How much insider selling is happening at Protagonist Therapeutics? Insiders have sold a total of 371,523 Protagonist Therapeutics shares in the last 24 months for a total of $15,191,715.79 sold. Protagonist Therapeutics Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 67)CEO, President, Secretary & Director Compensation: $1.03MMr. Asif Ali (Age 50)Executive VP & Chief Financial Officer Compensation: $631.04k1 recent tradesDr. Suneel K. Gupta Ph.D. (Age 66)Chief Development Officer Compensation: $719.21kDr. Mark Smythe Ph.D. (Age 59)Founder & VP Technology Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 53)Executive VP & General Counsel Ms. Carena SpiveyHead of HR & Senior VP of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 60)Executive VP & Chief Drug Discovery and Preclinical Development Officer Mr. Carter J. King (Age 53)Executive Vice President of Business Development Ms. Abha BommireddiExecutive Vice President of Portfolio & Program Management More Insider Trading Tools from MarketBeat Related Companies Intra-Cellular Therapies Insider Trades Roivant Sciences Insider Trades Revolution Medicines Insider Trades Lantheus Insider Trades Nuvalent Insider Trades Blueprint Medicines Insider Trades Elanco Animal Health Insider Trades Cytokinetics Insider Trades TG Therapeutics Insider Trades Viking Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:PTGX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
